IL165534A0 - Reduction of gelatin cross linking - Google Patents

Reduction of gelatin cross linking

Info

Publication number
IL165534A0
IL165534A0 IL16553404A IL16553404A IL165534A0 IL 165534 A0 IL165534 A0 IL 165534A0 IL 16553404 A IL16553404 A IL 16553404A IL 16553404 A IL16553404 A IL 16553404A IL 165534 A0 IL165534 A0 IL 165534A0
Authority
IL
Israel
Prior art keywords
reduction
cross linking
gelatin cross
gelatin
linking
Prior art date
Application number
IL16553404A
Other languages
English (en)
Original Assignee
Ivax Pharmaceuticals Sro
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ivax Pharmaceuticals Sro filed Critical Ivax Pharmaceuticals Sro
Publication of IL165534A0 publication Critical patent/IL165534A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
IL16553404A 2002-06-05 2004-12-02 Reduction of gelatin cross linking IL165534A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38611502P 2002-06-05 2002-06-05
PCT/US2003/017620 WO2003103582A2 (en) 2002-06-05 2003-06-05 Reduction of gelatin cross-linking

Publications (1)

Publication Number Publication Date
IL165534A0 true IL165534A0 (en) 2006-01-15

Family

ID=29736134

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16553404A IL165534A0 (en) 2002-06-05 2004-12-02 Reduction of gelatin cross linking

Country Status (7)

Country Link
US (1) US8895059B2 (es)
EP (1) EP1549299B1 (es)
AU (1) AU2003240536B2 (es)
ES (1) ES2524000T3 (es)
IL (1) IL165534A0 (es)
NZ (1) NZ537022A (es)
WO (1) WO2003103582A2 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0403247D0 (en) 2004-02-13 2004-03-17 Tillotts Pharma Ag A pharmaceutical composition
US7485323B2 (en) 2005-05-31 2009-02-03 Gelita Ag Process for making a low molecular weight gelatine hydrolysate and gelatine hydrolysate compositions
RU2406482C2 (ru) * 2005-07-26 2010-12-20 Никокс С.А. Фармацевтический состав нитрооксипроизводных нестероидных противовоспалительных средств
PE20081482A1 (es) * 2006-12-20 2008-12-23 Novartis Ag Capsulas de gelatina que contienen un acido
EP3187182B1 (en) 2008-09-02 2021-03-03 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
CN106822080A (zh) 2009-04-29 2017-06-13 阿马里纳药物爱尔兰有限公司 含有epa和心血管剂的药物组合物以及使用其的方法
PL2424356T3 (pl) 2009-04-29 2018-03-30 Amarin Pharmaceuticals Ireland Limited Stabilna farmaceutyczna kompozycja i sposoby jej stosowania
CN106074486A (zh) 2009-06-15 2016-11-09 阿马里纳药物爱尔兰有限公司 在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl‑c水平的组合物和方法
KR20120061955A (ko) * 2009-09-04 2012-06-13 캡슈겔 벨지엄 엔브이 방향 캡슐
SG10201405994UA (en) 2009-09-23 2014-10-30 Amarin Pharmaceuticals Ie Ltd Pharmaceutical Composition Comprising Omega-3 Fatty Acid And Hydroxy-derivative Of A Statin And Methods Of Using Same
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
NZ744990A (en) 2010-11-29 2019-10-25 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
WO2013070735A1 (en) 2011-11-07 2013-05-16 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
JP6307442B2 (ja) 2012-01-06 2018-04-04 アマリン ファーマシューティカルス アイルランド リミテッド 対象の高感度（ｈｓ−ｃｒｐ）のレベルを低下させる組成物および方法
MX2020008890A (es) 2012-06-29 2022-08-15 Amarin Pharmaceuticals Ie Ltd Metodos para reducir riesgo de evento cardiovascular en sujeto con terapia con estatina.
US20150265566A1 (en) 2012-11-06 2015-09-24 Amarin Pharmaceuticals Ireland Limited Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
KR101833280B1 (ko) * 2013-06-28 2018-02-28 한미약품 주식회사 두타스테라이드를 포함하는 경구용 연질 캡슐 제형
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
NL2017219B1 (en) 2016-07-22 2018-01-30 Rousselot B V Low cross-linking gelatine
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
TW201900160A (zh) 2017-05-19 2019-01-01 愛爾蘭商艾瑪琳製藥愛爾蘭有限公司 用於降低腎功能下降之個體中的三酸甘油酯之組合物及方法
PE20200747A1 (es) 2017-08-14 2020-07-24 Axcella Health Inc Composiciones de aminoacidos para el tratamiento de enfermedad hepatica
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
US10596136B2 (en) 2018-06-20 2020-03-24 Axcella Health Inc. Compositions and methods for the treatment of fat infiltration in muscle
MA50490A (fr) 2018-09-24 2020-09-02 Amarin Pharmaceuticals Ie Ltd Procédés de réduction du risque d'événements cardiovasculaires chez un sujet
CN111840247B (zh) * 2020-07-23 2022-06-07 青岛益青生物科技股份有限公司 一种具有抗交联作用的明胶空心胶囊及其制备方法
US11986452B2 (en) 2021-04-21 2024-05-21 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2467715A (en) * 1946-03-08 1949-04-19 Nat Starch Products Inc Manufacture of animal glue jellies
US2519487A (en) * 1947-07-02 1950-08-22 Merck & Co Inc Multivitamin preparation
US3456051A (en) * 1965-10-20 1969-07-15 Takeda Chemical Industries Ltd Soft gelatin sheet for soft gelatin capsule
US6090414A (en) * 1970-05-20 2000-07-18 Life Science Labs, Inc. Method and composition to reduce cancer incidence
US4255413A (en) * 1979-10-01 1981-03-10 Smithkline Corporation Gelatin capsule dosage unit containing triamterene
DD225426A1 (de) 1984-06-22 1985-07-31 Jenapharm Veb Verfahren zur herstellung stabiler gelantinezubereitungen
JPS63215641A (ja) * 1987-03-05 1988-09-08 Toyo Jozo Co Ltd ゼラチン皮膜組成物
FR2617047B1 (fr) 1987-06-23 1991-05-10 Sanofi Sa Composition de gelatine resistant au tannage, capsules a base de cette composition et leur application pharmaceutique, notamment au fenofibrate
DD295765A5 (de) 1988-07-18 1991-11-14 Arzneimittelwerk Dresden Gmbh,De Verfahren zur herstellung galenischer formulierungen fuer hydrophobe bzw. lipophile peptidwirkstoffe
US5186944A (en) * 1989-02-15 1993-02-16 Eimei Company Ltd. Therapeutic medicament for thrombosis
DE4201179A1 (de) * 1992-01-17 1993-07-22 Alfatec Pharma Gmbh Wirkstoff(e) enthaltendes granulat oder pellet mit einem geruest aus hydrophilen makromolekuelen und verfahren zu seiner herstellung
JPH06321541A (ja) 1993-05-18 1994-11-22 Etsuro Kato ジルコニア単分散球状超微粒子粉末の製造方法
CA2185803C (en) * 1994-03-18 2006-07-11 Edward M. Rudnic Emulsified drug delivery systems
US5620704A (en) * 1994-11-07 1997-04-15 Warner-Lambert Company Process for stabilizing gelatin products
CZ288631B6 (cs) * 1996-01-18 2001-08-15 Galena, A. S. Léčivé přípravky s obsahem cyklosporinu
WO1997033568A1 (en) 1996-03-12 1997-09-18 Novartis Ag Filled gelatin capsules having a reduced degree of cross-linking
JP2000002682A (ja) 1998-06-12 2000-01-07 Horiba Ltd ガス分析装置
US6136846A (en) * 1999-10-25 2000-10-24 Supergen, Inc. Formulation for paclitaxel
US6685961B1 (en) 2000-10-24 2004-02-03 Banner Pharmacaps, Inc. Colored gelatin-based formulations and method
CA2494069A1 (en) 2002-07-31 2004-02-05 Pharmacia Corporation Pellicle-resistant gelatin capsule

Also Published As

Publication number Publication date
NZ537022A (en) 2006-10-27
EP1549299A2 (en) 2005-07-06
ES2524000T3 (es) 2014-12-03
WO2003103582A2 (en) 2003-12-18
US8895059B2 (en) 2014-11-25
US20110097398A1 (en) 2011-04-28
EP1549299B1 (en) 2014-08-20
AU2003240536B2 (en) 2007-11-15
EP1549299A4 (en) 2010-12-15
WO2003103582A3 (en) 2004-07-29
AU2003240536A1 (en) 2003-12-22

Similar Documents

Publication Publication Date Title
IL165534A0 (en) Reduction of gelatin cross linking
HK1085244A1 (en) Quantification of gene expression
AU2003236991A8 (en) Representations of processes
HK1057885A1 (en) Succinate salt of o-desmethyl-venlafaxine o-desmethyl-venlafaxine
AU2003269187A8 (en) External stent
PT1470732T (pt) Fornecimento de informação de localização
EP1577280A4 (en) DEUTERATION PROCESS
AU2003238605A8 (en) Dynamic representations of processes
GB2387096B (en) Tomography of curved surfaces
EP1488046A4 (en) CONSTRUCTION METHODS
GB0226697D0 (en) Processing of data
AU2003257981A8 (en) Pellicle-resistant gelatin capsule
AU2003228133A8 (en) Reduction of unwanted immune reactions
GB0200595D0 (en) Quantitation of differential expression
GB0205336D0 (en) Data dimension reduction
PL356853A1 (en) Application of bacteriphages
GB2393207B (en) Means of assembly
AU2003217354A8 (en) Synthesis of sulfamidates
SI1537210T1 (sl) Lazna oligonukleotidna inhibicija ekspresije CD40
TW579826U (en) Structure of retainer
GB0212113D0 (en) Manufacture of signs
GB0202120D0 (en) Acoustical system of closed type
TW567775U (en) Structure of hairtie
AU2003209573A8 (en) Provision of graphic designs
TW533774U (en) Structure improvement of flyswatter